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Background: Both eukaryotic translation initiation factor 4E (eIF4E) and integrin αvβ6 play an important role in the
development and progression of cancer. The aim of this study was to investigate the expression of eIF4E and
Integrin αvβ6, their clinical significance as well as the two proteins’ correlation in colonic carcinoma tissues.
Results: The expression levels of eIF4E and integrin αvβ6 were analyzed in colon cancerous and paraneoplastic
tissues of 138 cases via tissue microarray (TMA)- immunohistochemistry. And their clinical significance as well as the
two proteins’ correlation was also investigated. The expression of eIF4E was significantly associated with clinical
TNM stage (P = 0.009), while T stage (P = 0.011) and TNM stage (P = 0.012) were significantly associated with integrin
αvβ6 expression. Moderately weak correlation exists between the two proteins (r =0.299, P <0.001). The survival
analysis by Kaplan-Meier and Cox regression model showed that protein expression of high eIF4E and positive
integrin αvβ6, as independent prognostic factors (RR = 2.417, P = 0.001 and RR = 2.393, P = 0.001), tended to have a
significantly poorer 5-year survival rate (P = 0.013 and 0.025, respectively, the log-rank test).
Conclusion: eIF4E and Integrin αvβ6 were indicators of tumor’s progression and poor prognosis of patients with
colon cancer. And the potential signaling loop involving them may provide a helpful therapeutic target in
prevention and treatment of colon cancer.
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Colon cancer is one of the leading causes of cancer-related
deaths worldwide. With the improvement of current living
standards and environmental degradation, its morbidity
has been on the rise year by year [1]. Both eIF4E and
integrin αvβ6 can play important roles in the development
and progression of colonic carcinoma [2-4].
Eukaryotic initiation factor 4E (eIF4E), a 25-kDa cap
binding protein, delivers cellular mRNAs to the eIF4F
translation initiation complex by binding the 5′-cap
structure of these mRNAs [5]. Only about 10% of mRNAs* Correspondence: junniu120@163.com
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unless otherwise stated.with 5′UTRs of sufficient length (>200 nt) and three-
dimensional steric hindrance require the assistance of the
eIF4E for efficient translation [6]. eIF4E overexpression
can selectively affect transport of specific transcripts and
up-regulate the translation of a limited pool of mRNAs
with long G-C rich 5′-UTRs and complex structure, en-
coding proteins involved in cellular growth, angiogenesis,
survival, tumorigenesis, and metastasis,such as cyclin D1,
c-myc, vascular endothelial growth factor (VEGF), fibro-
blast growth factor (FGF-2), matrix metalloprotease 9
(MMP-9) [2,7-9]. It is considered as a central regulator of
malignancy. eIF4E overexpression has been demonstrated
in carcinomas of breast, colon, prostate, bladder, cervix,
lung, head and neck (reviewed in [9]).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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molecules composed of two non-covalently bound trans-
membrane subunits (18 α-subunits and 8 β-subunits re-
ported) [10]. These proteins collectively mediate cellular
adhesion to extracellular matrix (ECM) and modulate cell
proliferation, migration, invasion, and survival by activating
intracellular signaling pathways [11]. The β6 integrin
subunit with αv, its sole binding partner, is an epithelial-
cell-restricted antigen, which is reported to be expressed
in epithelial cancers (lung, breast, pancreas, ovary, oro-
pharynx and colon), as well as during tissue remodeling
events (e.g., fibrosis, wound healing) [12,13]. Integrin
αvβ6 plays an pivotal role in various aspects of cancer
progression [14].
Integrin-mediated signals have been known to contribute
to malignancy by regulating transcription [15]. On the
other side, recent studies indicated they could also
selectively enhance translation initiation of protein synthe-
sis relating to malignancy, through activation of eIF4E via
signal pathway of PI-3 K/Akt/mTOR and Ras/ERK/MNK
[16-18]. However, the correlation between eIF4E and
integrin αvβ6 and their possible interaction at molecular
level are still not clearly known. The aim of our present
study was to explore the coexpression and clinical signifi-
cance of eIF4E combined with integrin αvβ6 in colon can-
cer, which could provide a theoretical basis for further
study of molecular mechanism in therapeutic intervention.
Results
The expression of integrin β6 and eIF4E in normal and
neoplastic colon tissue
For eIF4E cohort, 10 tumor cases could not be stained
as negative expression, and positive rate was 92.8%, with
74 high expression (Figure 1, Table 1). For integrin αvβ6,
54 cases were positive expression, and 84 were negative
(Figure 2, Table 1). And the normal para-neoplastic tissues
for the two markers were all negative staining.
Clinicopathologic data
After our TMA-IHC staining, all 138 cases for eIF4E and
integrin αvβ6 were assessable. The detailed clinicopatho-
logic data for eIF4E and integrin αvβ6 are outlined in
Table 1.
Association between eIF4E and clinicopathologic
variables and patient survival
There was significant association between eIF4E and
TNM stage (P = 0.009). The high eIF4E rate of TNM
III-IV specimens was 65.2%, much more than that of
TNM I – II 43.1%. According to the standard of P < 0.05,
eIF4E expression has no significant association with other
clinicopathologic factors, tumor’s anatomical location in-
cluded, while P-Values of T stage, N stage and M stage on
eIF4E were all between 0.05 and 0.10.Survival curves were generated through the Kaplan-
Meier survival analysis, Patients with high eIF4E ex-
pression had a significantly poorer overall survival than
those with low expression (P = 0.013, The log-rank test,
χ2 = 6.418). Patient survival over time on eIF4E expression
is illustrated in Figure 3.
Association between integrin αvβ6 and clinicopathologic
variables and patient survival
There was significant association between integrin αvβ6
expression and T stage (P = 0.011),TNM stage (P = 0.012).
The positive integrin αvβ6 rate of TNM III-IV specimens
was 50.0%, much more than that of TNM I – II 29.2%.
Based on the standard of P < 0.05,integrin αvβ6 expression
has no association with other clinicopathologic factors
including age, gender, tumor’s anatomical location, path-
ology grade, N stage and M stage.
Patients with high positive αvβ6 expression had a signifi-
cantly poorer overall survival rate than those with negative
expression (P = 0.025, The log-rank test, χ2 = 5.012). Pa-
tient survival over time on eIF4E expression is illustrated
in Figure 4.
The correlation between integrin αvβ6 and eIF4E
expression in colon cancer
Positive integrin αvβ6 expression was observed in 52.7%
of high eIF4E expression tissue, while the rate in low
eIF4E expression tissue was 23.4%. Based on the Spearman
correlation analysis, integrin αvβ6 expression had a positive
correlation with eIF4E expression (r =0.299, P <0.001,
Table 2).
These 138 cases were stratified according to eIF4E and
integrin αvβ6 expression into 4 groups: group 1, low
eIF4E/(−) integrin αvβ6 (n = 49); group 2, low eIF4E/(+)
integrin αvβ6 (n =15); group 3, high eIF4E/(−) integrin
αvβ6 (n =35); and group 4, high eIF4E/(+) integrin αvβ6
(n = 39). Patients with high eIF4E/(+) integrin αvβ6 had a
significantly poorer overall survival rate than other groups
(P = 0.028, The log-rank test, χ2 = 9.091). Patient survival
over time on eIF4E with integrin αvβ6 expression is illus-
trated in Figure 5.
Univariate and multivariate analysis for prognosis of
patients with colon cancer
Univariate and multivariate data analyses were performed
using the Cox proportional hazards regression model to
determine the prognostic value of eIF4E and integrin αvβ6
expression. Older age at diagnosis, high eIF4E expression
and positive expression of αvβ6 were the factors to predict
a poor prognosis in univariate analysis (P < 0.001,0.016,
0.028,respectively) (Shown in Table 3). Then the variables
with P < 0.10 were chosen to conduct multivariate analysis,
we revealed that high eIF4E expression and positive ex-
pression of αvβ6 were unfavorable independent prognostic
Figure 1 eIF4E expression in human colonic cancer. First row: (a), (b), (c) (Scale bar 200 μm.); second row: (d), (e), (f), corresponding to each
figure above (Scale bar 100 μm). (a) and (d) was obtained from paracancerous normal tissue of patient with colon cancer, with negative staining.
(b) and (e) was obtained from colonic carcinoma tissue, with low eIF4E expression. (c) and (f) was obtained from colonic carcinoma, with high
eIF4E expression.
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0.001,respectively), while increased age, poor/undifferenti-
ated pathology grade were also independent prognostic
factors (RR: 1.114 and 2.195; P < 0.001 and 0.003, respect-
ively) (Shown in Table 3).
Discussion
Colorectal cancer has a higher morbidity and mortality
in developed countries [19]. Despite improvements made
in screening and treatments during the past years, the
clinical outcome of colon cancer remains unsatisfactory.
Understanding the molecular mechanism of tumorigen-
esis would contribute to treatment of patients with this
disease.
Over the past decades, the contribution of the mRNA
cap-binding protein, eIF-4E, to malignant transformation
and progression has been illuminated. eIF4E gene is re-
ported to be recognized as an proto-oncogene in vivo,and
the extent of eIF4E overexpression can predict cancer
recurrence and outcome in head neck squamous cell
carcinoma (HNSCC), breast cancer and lung cancer
[9,20]. In our present study, patients with high expression
eIF4E tended to have a poorer prognosis than those with
low expression. And the level of eIF4E expression had
significant association with TNM stage, while P-Values of
T stage, N stage and M stage respectively on eIF4E were
all between 0.05 and 0.10. From this point, we could
speculate that, to some extent, the expression of eIF4E
was related to tumor’s metastasis and progression. Inbrief, the association between eIF4E expression and
poor prognosis could be explained by the hypothesis of
“strong and weak mRNAs”. Translation of strong mRNAs
(e.g. those encoding housekeeping proteins such as beta-
actin) will quickly reach a maximum in the presence of
low levels of free eIF4E while weak mRNAs are poorly
translated. With the increasing number of free activated
eIF4E, the translation of these “weak mRNAs” relating to
malignancy is disproportionately enhanced, which con-
tributes to the malignant activities [21,22].
The integrin αvβ6 occurs in many epithelial tumors
and has been considered to play a prominent role in
tumor invasion and metastasis [14]. Recently, it was re-
ported as an independent unfavorable prognostic indicator
in aggressive colonic and gastric carcinomas of humans
[12,13], which was confirmed in our study according to
the Cox regression model. Similar to the study of Bates
[12], our results also showed that the αvβ6 expression
were significantly associated with clinical stage and the
depth of invasion of tumors. These results could be ex-
plained logically by our previous studies, that αvβ6
serves to direct growth factor-activated ERK to down-
stream cytoplasmic targets involved in regulating cell
growth, apoptosis and cytoskeletal reorganization [23,24],
and in promoting cellular migration by mediating MMP-9
secretion [25].
Integrin-dependent translational control in cancer pro-
gression has been widely investigated and recognized in
recent years [16]. The mechanism involves the ability of
Table 1 Association between eIF4E expression, integrin αvβ6 expression and clinicopathologic variables in colon
cancer cases
Clinicopathological factors n eIF4E expression Value Integrin αvβ6 expression P Value
High (n = 74) Low (n = 64) Positive (n = 54) Negative (n = 84)
Gender 0.345 0.927
Male 76 38 38 30 46
Female 62 36 26 24 38
Age(years) 0.874 0.108
<60 70 38 32 32 38
≥60 68 36 32 22 46
Tumor anatomical location 0.634 0.773
Right hemicolon cancer 72 32 40 43 29
Left hemicolon cancer 66 32 34 41 25
T stage 0.072 0.011
T1# 1 0 1 0 1
T2# 13 8 5 2 11
T3 55 23 32 17 38
T4 69 43 26 35 34
N stage 0.067 0.109
N0 76 34 42 26 50
N1 44 28 16 17 27
N2 18 12 6 11 7
M stage
M0 114 57 57 0.063 40 74 0.034
M1 24 17 7 14 10
TNM stage 0.009 0.012
I - II 72 31 41 21 51
III-IV 66 43 23 33 33
Differentiation 0.959 0.209
Well 50 26 24 15 35
Moderate 55 30 25 23 32
Poor/undifferentiated 33 18 15 16 17
Survival (60-month follow-up) 0.013* 0.025*
Death 63 40 23 30 33
Censored 75 34 41 24 51
Footnote: #Date of T1 and T2 were combined into one set for chi-square test.
*Log-rank test.
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ERK-MNK pathway, which subsequently enhance eIF4E
function through the inhibition of 4E-BP1 [16-18,26] and
phosphorylation of eIF4E at ser209 by MNK [27]. Re-
leased eIF4E, accompanied with eIF4G and eIF4A, is
then able to engage and activate eIF4F complex, leading
to translation initiation of genes associated with malig-
nancy. The role of integrin on translation has been ad-
dressed in models requiring integrin β3, integrin β4,
and Integrin β1 (reviewed in [16]).In this study, we revealed that high expression of eIF4E
combined with positive αvβ6 can predict a poorer progno-
sis. And their expressions were positively correlated in
colon cancer. However, integrin αvβ6 dependent transla-
tional control hasn’t been investigated before. As a member
of integrin families, integrin αvβ6 could trigger ERK path-
way, leading to the activation of downstream signals
[23,24]. According to the theoretical basis mentioned above,
we can logically speculate that integrin αvβ6 probably could
also mediate the activation of eIF4E, leading to translation
Figure 2 Integrin β6 expression in human colonic cancer. First row: (a), (b), (c) (Scale bar 200 μm.); second row: (d), (e), (f), corresponding to
each figure above (Scale bar 100 μm). (a) and (d) was obtained from paracancerous normal tissue of patient with colon cancer, with negative
staining. (b) and (e) was obtained from colonic carcinoma tissue,with negative Integrin β6 expression. (c) and (f) was obtained from colonic
carcinoma, with positive Integrin β6 expression.
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bold but reasonable hypothesis is that the activated eIF4E
could up-regulate the protein synthesis of Integrin β6, as
the mRNA of Integrin β6 has long 5′-UTRs with rich GC,
complex structure (Gene ID: 3694, from NCBI), meeting
the criteria of “weak mRNAs”. Thus, a signal loop involving
eIF4E andαvβ6 probably exists to play a key role in tumor
cellular growth and migration. Of course, our further workFigure 3 Overall survival according to eIF4E expression (P =
0.013, The log-rank test).is to demonstrate our hypotheses and determine whether it
can be translated into real clinical benefit.
Conclusion
In summary, our findings indicated that the levels of
eIF4E and αvβ6 expression are elevated in colonic carcin-
oma, which were associated with tumor progression and
poor prognosis of patients with colon cancer. Additionally,Figure 4 Overall survival according to αvβ6 expression (P =
0.025, The log-rank test).
Table 2 Correlation between integrin αvβ6 expression and
eIF4E expression in human colonic carcinoma tissues
(r = 0.299, P < 0.001)
eIF4E Integrin αvβ6 Total
Negative Positive
Low 49 15 64
High 35 39 74
Total 84 54 138
Niu et al. Cell & Bioscience 2014, 4:23 Page 6 of 8
http://www.cellandbioscience.com/content/4/1/23the expression of eIF4E and integrin αvβ6 are moderate-
poorly correlated, and with cautious speculation, they may
interact with each other at molecular levels, with signifi-
cant implications for therapeutic intervention.
Materials and methods
Clinical samples
Our study was a retrospective analysis of patients who
had been diagnosed as colon cancer at Qilu Hospital of
Shandong University, between January 2006 and July 2008.
Included in this study, patients with colon cancer must
have received surgical resection as the initial treatment
modality without major perioperative complications, had
adequate archived tissue kept and complete clinicopatho-
logic data obtained . This resulted in a collection of tissue
from 138 patients, 76 males and 62 females with a median
age of 57.4 years and an age range of 22–86 years. Based
on tumor’s anatomical location, we classified colon cancer
into right hemicolon cancer (including cecum, ascending
colon, and right transverse colon) and left hemicolon
cancer (including left transverse colon and descendingFigure 5 Overall survival according to eIF4E with integrin αvβ6
expression (P = 0.028, The log-rank test).colon). Among those, 63 (45.7%) were confirmed cancer-
specific death within 5 years of prognosis and 75 (54.3%)
were censored as their case follow up was discontinued or
patients were alive beyond 60 months or died of reasons
other than colon cancer. The pathologic tumor–node–
metastasis (TNM) classification was based on the criteria
of the International Union Against Cancer (2009). The study
complied with the requirements of The Ethics Committee
of Qilu Hospital, Shandong University. And the detailed
case characteristics are summarized in Table 1.
Antibodies and TMA-immunohistochemistry
As primary antibodies, prediluted anti-Integrin β6 poly-
clonal rabbit antibody (1:200; Proteintech Group, Inc., Cat.
No.19695-1-AP, Chicago, USA), anti- eIF-4E rabbit mono-
clonal antibody (1:100; Epitomics, Inc., Cat.No. 1598–1,
Burlingame, USA) were used. HRP secondary antibodies
and DAB kit were obtained from ZSGB-BIO (Beijing
ZSJQB Co., Ltd., Beijing, China).
First, the 138 patients’ paraffin blocks were collected from
the archive of Pathology Department of Qilu Hospitital.
Then colonic tumor tissue microarrays (TMA) were con-
structed as described previously [28], and two successive
5 μm-thick TMA sections were cut ready for immunohis-
tochemistry. There were 150 spaced, array pattern cores
(1 mm in diameter) on either section containing 138
carcinoma specimen and 12 paracancerous normal tissue.
Next, immunohistochemical staining for the two markers
was done on TMA sections as follows. Sections were incu-
bated for 60 min at 65°C, deparafinized and rehydrated
using a xylene and ethanol series. Then microwave antigen
retrieval was performed: sections were spaced in 250 mL
citrate buffer (pH 6.4) for microwaving, with high-
temperature for 5 minutes and 40°C for 15 minutes.
After cooled to room temperature and washed in PBS,
the tissue was quenched of endogenous peroxidase by
3% H2O2 for 20 minutes, and blocked in goat serum 37°C
for 40 minutes. Primary antibody incubation was then
done by either antibody respectively overnight at 4°C. The
second day, TMA tissue was incubated with universal IgG
antibody-Fab-HRP polymer for 30 min; then, DAB
and Hematoxylin were stained and terminated in time
sequentially. Finally, the samples were observed under
light microscope (Olympus Corp, Tokyo, Japan) after
sealed with neutral tree gum on slides.
Evaluation of and integrin αvβ6 immunohistochemistry
integrin αvβ6 was expressed both in cytoplasm and on
cellular membrane, mainly seen on the internal surface
of the tumor epithelial cell membrane [29]. The expression
of eIF4E was mainly observed in cytoplasm of tumor cells.
Semi-quantitative expression levels were evaluated by three
individuals based on the average intensity and percentage
of positively stained tumor cells. Staining intensity was
Table 3 Univariate and multivariate analysis of association of clinicopathologic features with 5-year survival in colon
cancer cases
Variable Univariate analysis Multivariate analysis
Relative risk 95% CI P Value Relative risk 95% CI P Value
Age at diagnosis 1.091 1.063, 1.119 <0.001 1.114 1.083, 1.145 <0.001
Gender
Male 1.000(Ref.) - -
Female 0.729 0.438, 1.212 0.223
Tumor anatomical location
Right hemicolon cancer 1.000(Ref.) - -
Left hemicolon cancer 1.000 0.610,1.640 0.999
T stage
T1 0.000 0.000, >105 0.973
T2 0.951 0.395, 2.290 0.910
T3 1.152 0.685, 1.937 0.595
T4 1.000(Ref.) - -
N stage
N0 1.000(Ref.) - -
N1 1.308 0.760, 2.252 0.332
N2 1.356 0.646, 2.843 0.421
M stage
M0 1.000(Ref.) - -
M1 1.308 0.697, 2.454 0.403
TNM stage
I 1.000(Ref.) - -
II 0.634 0.242, 1.664 0.355
III 0.998 0.378, 2.638 0.997
IV 1.029 0.362, 2.922 0.957
Pathology Grade
Well 1.000(Ref.) - - 1.000(Ref.) - -
Moderate 1.666 0.912, 3.046 0.097 1.348 0.721, 2.519 0.349
Poor/undifferentiated 1.845 0.950, 3.583 0.070 2.915 1.453, 5.848 0.003
eIF4E
Low expression 1.000(Ref.) - - 1.000(Ref.) - -
High expression 1.885 1.128, 3.150 0.016 2.417 1.413, 4.134 0.001
αvβ6
Negative 1.000(Ref.) - - 1.000(Ref.) - -
Positive 1.741 1.061, 2.857 0.028 2.393 1.421, 4.028 0.001
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yellow), 2 (moderate staining = yellow brown), and 3
(strong staining = brown). And the percentage of stained
tumor cells was scored as 0 (no positive cells), 1 (less than
25% positive cells), 2 (25–50% positive cells), 3 (more than
50-75% positive cells), and 4 (more than 75% positive
cells). Consensus results were determined for cores with
different initial scores, and ultimate scoring was validatedby a consultant histopathologist. An intensity score ≥2
with at least 50% of tumor cells with positive eIF4E stain-
ing was used to classify tumor patients with high expres-
sion group,and the others including negative staining were
considered as low expression group. In the tumor,
positive αvβ6 staining was judged by the presence of
an unequivocal brown staining in the cytoplasm of 10%
or more of tumor cells, the rest were negative.
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Statistical analyses were performed with SPSS 13.0
software. A chi-square test of cross-tabulations and a
Fisher exact test were used to examine the relationship
between the expression of eIF4E and integrin αvβ6 and
their clinicopathologic characteristics. Survival analyses
were conducted by the Kaplan-Meier method and the log-
rank test. A Spearman correlation was applied to evaluate
the relationship between eIF4E and integrin αvβ6 ex-
pression levels. Both univariate and Multivariate analysis
for cancer specific deaths were done with the Cox propor-
tional hazard model. P-values < 0.05 was considered to be
statistically significant.
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